TITLE

Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer

AUTHOR(S)
Douglas, Claire A.; Ellershaw, John
PUB. DATE
November 2003
SOURCE
Palliative Medicine;Nov2003, Vol. 17 Issue 7, p638
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Paraneoplastic encephalomyelitis (PEM) is a form of neurological dysfunction caused by the remote effect of small cell lung cancer (SCLC) on the brain. In certain cases it is associated with the presence of Anti-Hu antibodies. Up to 65% of patients with SCLC and PEM, who have Anti-Hu antibodies present, die of neurological complications rather than tumour progression. Chemotherapy is not believed to be beneficial. We describe a 58- year-old lady who was bed-bound and significantly disabled from paraneoplastic cerebellar degeneration. Her serology confirmed the presence of Anti-Hu antibodies and SCLC was confirmed at bronchoscopy. Following six courses of chemotherapy her neurological symptoms have remarkably improved, both subjectively and objectively, such that she is now independently mobile with a walking frame. Her tumour is still evident on bronchoscopy. We suggest that people with SCLC who are significantly disabled by neurological symptoms, should be tested for serum anti-neuronal antibodies and if Anti-Hu antibody positive, anti-neoplastic treatment should be considered despite poor performance status.
ACCESSION #
10945121

 

Related Articles

  • Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. Casadio, Chiara; Guarize, Juliana; Donghi, Stefano; Di Tonno, Clementina; Fumagalli, Caterina; Vacirca, Davide; Dell'Orto, Patrizia; De Marinis, Filippo; Spaggiari, Lorenzo; Viale, Giuseppe; Barberis, Massimo // American Journal of Clinical Pathology;Oct2015, Vol. 144 Issue 4, p629 

    Objectives: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that has revolutionized the diagnosis and staging of lung cancer. The goal of the present study was to investigate the yield and applicability of molecular...

  • Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Bahl, A; Falk, S // British Journal of Cancer;5/1/2001, Vol. 84 Issue 9, p1143 

    Editorial. Discusses the controversy surrounding the optimal chemotherapy regimen for effective treatment of patients with advanced non-small cell lung cancer (NSCLC). Dependence of NSCLC patients on systemic chemotherapy for increasing survival; List of second generation drugs used in the...

  • Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Pujol, J-L; Carestia; Daurès, J-P // British Journal of Cancer;7/1/2000, Vol. 83 Issue 1, p8 

    Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug combinations and schedules remain to be defined and there is hitherto no world-wide accepted standard regimen. Cisplatin, an alkylating agent with high putative toxicity is currently widely used although its...

  • Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Sekine, I; Nishiwaki, Y; Kakinuma, R; Kubota, K; Hojo, F; Matsumoto, T; Ohmatsu, H; Goto, K; Kodama, T; Eguchi, K; Shinkai, T; Tamura, T; Ohe, Y; Kunitoh, H; Yoshimura, K; Saijo, N // British Journal of Cancer;3/24/2003, Vol. 88 Issue 6, p808 

    Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in...

  • Chemotherapy in the treatment of non-small cell lung cancer. Hainsworth, John D. // American Family Physician;5/1/1997, Vol. 55 Issue 6, p2265 

    Focuses on the treatment of non-small cell lung cancer in the United States. Effective treatment of metastatic non-small cell lung cancer; Outcome of randomized trials comparing chemotherapy with supportive care in patients with non-small cell lung cancer; Locally advanced unresectable cancer;...

  • Surgery plus chemo may improve survival in lung cancer. Hurley, Mary Lou // RN;Apr94, Vol. 57 Issue 4, p79 

    Reports that preoperative chemotherapy increased the median survival in a group of patients with non-small-cell lung cancer. `New England Journal of Medicine' as source; Use of intravenous chemo; Lower rate of recurrence; Disease-free survival.

  • Higher doses during first-cycle chemo increase survival. Rodman, Morton J.; Hurley, Mary Lou // RN;May94, Vol. 57 Issue 5, p81 

    Reports on a French study on the benefits derived from higher initial dosage of chemotherapeutic drugs for patients with limited small-cell lung cancer. Assignment of variable doses of cisplatin and cyclophosphamide; Comparison of survival rates and occurrences of side effects.

  • Chemotherapy for non-small cell lung cancer. Carbone, David P. // BMJ: British Medical Journal (International Edition);10/7/95, Vol. 311 Issue 7010, p889 

    Editorial. Comments on a study published on the October 7, 1995 issue of the `British Medical Journal' on the effectivity of chemotherapy for non-small cell lung cancer. Indication of little benefit from chemotherapy; Modest clinical impact of these benefits; Limitations of the study;...

  • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Alberti, W.; Anderson, G. // BMJ: British Medical Journal (International Edition);10/7/95, Vol. 311 Issue 7010, p899 

    Evaluates the effect of cytotoxic chemotherapy on survival in patients with non-small cell lung cancer. Cisplatin-containing chemotherapy regimens; Radical radiotherapy; Detrimental effect of long-term use of alklating agents.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics